Cargando…
RETRACTED ARTICLE: IRE1α-XBP1 but not PERK inhibition exerts anti-tumor activity in osteosarcoma
Osteosarcoma (OS) is the most common primary malignant bone tumor. However, the therapeutic results of the advanced cases at the first visit were still extremely poor. Therefore, more effective therapeutic options based on molecular profiling of OS are needed. In this study, we investigated the func...
Autores principales: | Sasa, Keita, Saito, Tsuyoshi, Kurihara, Taisei, Hasegawa, Nobuhiko, Sano, Kei, Kubota, Daisuke, Akaike, Keisuke, Okubo, Taketo, Hayashi, Takuo, Takagi, Tatsuya, Yao, Takashi, Ishijima, Muneaki, Suehara, Yoshiyuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777567/ https://www.ncbi.nlm.nih.gov/pubmed/35201455 http://dx.doi.org/10.1007/s12672-021-00453-2 |
Ejemplares similares
-
Retraction Note to: IRE1α-XBP1 but not PERK inhibition exerts anti-tumor activity in osteosarcoma
por: Sasa, Keita, et al.
Publicado: (2022) -
IRE1α-XBP1 inhibitors exerted anti-tumor activities in Ewing’s sarcoma
por: Tanabe, Yu, et al.
Publicado: (2018) -
Establishment of Rapid and Accurate Screening System for Molecular Target Therapy of Osteosarcoma
por: Sasa, Keita, et al.
Publicado: (2022) -
Nanostring-based screening for tyrosine kinase fusions in inflammatory myofibroblastic tumors
por: Kurihara, Taisei, et al.
Publicado: (2020) -
Novel mechanism of enhancing IRE1α-XBP1 signalling via the PERK-ATF4 pathway
por: Tsuru, Akio, et al.
Publicado: (2016)